UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000057234
Receipt number R000065419
Scientific Title A registry study of CHemotherApy-ineligible Metastatic hormone-sensitive Prostate cancer
Date of disclosure of the study information 2026/01/01
Last modified on 2025/03/07 09:59:29

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A registry study of CHemotherApy-ineligible Metastatic hormone-sensitive Prostate cancer

Acronym

CHAMP study

Scientific Title

A registry study of CHemotherApy-ineligible Metastatic hormone-sensitive Prostate cancer

Scientific Title:Acronym

CHAMP study

Region

Japan


Condition

Condition

metastatic hormone-sensitive prostate cancer

Classification by specialty

Urology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To investigate the current state of treatment and prognosis for metastatic hormone-sensitive prostate cancer (mHSPC) that does not receive chemotherapy.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Time to CRPC-progression

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male

Key inclusion criteria

1) Those diagnosed with mHSPC
2) Those aged 20 years or older at the time of consent
3) Those who are able to take medication orally
4) Those receiving drug therapy for mHSPC that does not include chemotherapy
5) Those who have given written consent to participate in this study

Key exclusion criteria

1) Those who have not had a histological diagnosis of prostate cancer
2) Those who have had a malignant tumour other than prostate cancer within the last 3 years
3) Those who have serious (requiring hospitalisation) and uncontrollable complications other than malignant tumours
4) Those who have a seizure disorder requiring anticonvulsant treatment (except those in a clinically stable period or those without seizures)
5) Those with severe liver dysfunction
6) Those with a history of hypersensitivity to the components of the mHSPC treatment drug
7) Those who are unable or unwilling to cooperate with the procedures of this study
8) Those who are deemed by the treating physician to be unsuitable subjects for this study.

Target sample size

250


Research contact person

Name of lead principal investigator

1st name Kohei
Middle name
Last name Hashimoto

Organization

Sapporo Medical University School of Medicine

Division name

Department of Urology

Zip code

0608543

Address

Minami 1-Jo, Nishi 16 Cho-me, Chuo-ku, Saspporo

TEL

011612111

Email

kohei@cj9.so-net.ne.jp


Public contact

Name of contact person

1st name Kohei
Middle name
Last name Hashimoto

Organization

Sapporo Medical University School of Medicine

Division name

Department of Urology

Zip code

0608543

Address

Minami 1-Jo, Nishi 16 Cho-me, Chuo-ku, Saspporo

TEL

011612111

Homepage URL


Email

kohei@cj9.so-net.ne.jp


Sponsor or person

Institute

Department of Urology, Sapporo Medical University School of Medicine

Institute

Department

Personal name



Funding Source

Organization

not available

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Sapporo Medical University

Address

Minami 1-Jo, Nishi 16 Cho-me, Chuo-ku, Saspporo

Tel

011-611-2111

Email

to-rskk@sapmed.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2026 Year 01 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2025 Year 02 Month 01 Day

Date of IRB


Anticipated trial start date

2025 Year 05 Month 01 Day

Last follow-up date

2031 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

not available


Management information

Registered date

2025 Year 03 Month 07 Day

Last modified on

2025 Year 03 Month 07 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000065419